Libre 3 Sensors: With Second Plant Online, Abbott Aims For Under-Penetrated ‘Intensive Insulin’ Segment

International sales could be a key driver as firm also looks to partnerships with insulin pump companies.

Abbott’s international sales could be a key driver as firm looks to partnerships with insulin pump companies.

Despite previous supply challenges, Abbott said in its earnings call that it continues to report robust growth in the continuous glucose monitoring (CGM) market. (Shutterstock)
Key Takeaways
  • Abbott launched a new 323,000-square-foot manufacturing facility in Kilkenny, Ireland, employing more than 800 people to ramp up FreeStyle Libre 3 sensor production. 

      With the launch of its second manufacturing plant, Abbott is ramping up production of its FreeStyle Libre 3 sensors, aiming to expand its reach in the under-penetrated intensive insulin-using segment.

      Welcome to Medtech Insight

      Create an account to read this article

      More from Business

      Nyxoah Launches FDA-Cleared Genio System For OSA As Rival Inspire Files Patent Suit

       
      • By 

      After receiving FDA clearance for its Genio sleep apnea implant, Nyxoah plans a major US rollout despite a patent suit from rival Inspire Medical. Genio offers bilateral nerve stimulation as a CPAP alternative, with strong trial results.

      Inaccurate Carbon Dioxide Readings Prompt Class I Recall Of Draeger Ventilation Filters

       

      Draeger Medical has recalled certain SafeStar and TwinStar ventilation filters after reports of serious injuries caused by misleading carbon dioxide readings.

      After Thought-Control Demo, Synchron Plans Pilot Study With Upgraded BCI On Path To Pivotal Trial

       
      • By 

      Synchron is preparing a pilot study of its fully wireless, second-gen brain-computer interface after an ALS patient controlled an iPad solely by thought. If all goes as planned, Synchron’s BCI will move into pivotal trials in 2026.

      Apreo Health Raises $130M, First Patient Treated In US Clinical Trial

       

      Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.

      More from Device Area

      Apreo Health Raises $130M, First Patient Treated In US Clinical Trial

       

      Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.

      NAD Alerts Agendia Over Endorsing Physician’s Ties To Firm

       
      • By 

      The National Advertising Division (NAD) alerted Agendia to improve disclosure regarding a physician endorsing its MammaPrint test. The physician's ties to Agendia were inadequately revealed in LinkedIn posts.

      FDA Ends Effort To Regulate LDTs By Rescinding Final Rule

       

      Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.